The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Phosphodiesterase type 5 inhibitors for erectile dysfunction
Abstract
This is our first presentation of Great Drug Classes, and we start with a description of phosphodiesterase type 5 inhibitors and their use in erectile dysfunction. This is an in‐depth review of this class of drugs, offering the reader a description of how they work, in which conditions they may be particularly beneficial, and a comparison of the three different drugs. It is of necessity longer than the usual manuscript accepted for the BJU International, with a full list of references. The cyclic nucleotide signalling pathway mediates the smooth‐muscle relaxing effects of nitric oxide necessary for normal erectile function. Down‐regulation of this pathway is central to the pathophysiology of many forms of erectile dysfunction (ED), which is often associated with other chronic diseases (e.g. hypertension, type 2 diabetes mellitus) and treatments (e.g. certain drugs, radical prostatectomy). Conversely, selective inhibition of the enzyme that catalyses the degradation of cGMP (phosphodiesterase type 5, PDE‐5) promotes erectile responses to sexual stimulation. The successful launch and commercialization of the selective PDE5 inhibitor (PDE5I) sildenafil transformed the treatment of ED, not only by providing an effective, well tolerated oral ED therapy, but also by fostering greater candour about the problem among men. Sildenafil is highly effective in promoting erectile responses across a wide spectrum of severity and causes of ED, including patients with ED that is often refractory to treatment. The recent advent of vardenafil, which has the highest in vitro potency of all available PDE5Is, and tadalafil, which has a prolonged half‐life that may enable couples to have sexual activity with less planning, represent further advances. Other PDE5Is offering further potential improvements are under active investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rosen, R. C., Riley, A., Wagner, G., Osterloh, I. H., Kirkpatrick, J., & Mishra, A. (1997) · Urology · doi:10.1016/s0090-4295(97)00238-0 · Cited by 5,849
Oral Sildenafil in the Treatment of Erectile Dysfunction
Goldstein, I., Lue, T. F., Padma-Nathan, H., Rosen, R. C., Steers, W. D., & Wicker, P. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199805143382001 · Cited by 2,120
Self-citation(1999) · doi:10.1016/s0090-4295(99)00099-0 · Cited by 1,051
Effect of Lifestyle Changes on Erectile Dysfunction in Obese Men: A Randomized Controlled Trial
Esposito, K., Giugliano, F., Di Palo, C., Giugliano, G., Marfella, R., D'Andrea, F., D'Armiento, M., & Giugliano, D. (2004) · JAMA · doi:10.1001/jama.291.24.2978 · Cited by 841
Rosen, R. C., Fisher, W. A., Eardley, I., Niederberger, C., Nadel, A., & Sand, M. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904125003467 · Cited by 588
Montorsi, F., Luigi, G. G., Strambi, L. F., Da Pozzo, L. F., Nava, L., Barbieri, L., Rigatti, P., Pizzini, G., & Miani, A. (1997) · Journal of Urology · doi:10.1016/s0022-5347(01)64227-7 · Cited by 547
SHABSIGH, R., KAUFMAN, J. M., STEIDLE, C., & PADMA-NATHAN, H. (2004) · Journal of Urology · doi:10.1097/01.ju.0000132389.97804.d7 · Cited by 406
Porst, H., Padma-Nathan, H., Giuliano, F., Anglin, G., Varanese, L., & Rosen, R. (2003) · Urology · doi:10.1016/s0090-4295(03)00359-5 · Cited by 320
Cited by
Shamloul, R., & Ghanem, H. (2013) · The Lancet · doi:10.1016/s0140-6736(12)60520-0 · Cited by 1,091
Mammalian Cyclic Nucleotide Phosphodiesterases: Molecular Mechanisms and Physiological Functions
Francis, S. H., Blount, M. A., & Corbin, J. D. (2011) · Physiological Reviews · doi:10.1152/physrev.00030.2010 · Cited by 639
Mechanisms of Penile Erection and Basis for Pharmacological Treatment of Erectile Dysfunction
Andersson, K.-E. (2011) · Pharmacological Reviews · doi:10.1124/pr.111.004515 · Cited by 392
Erectile Dysfunction in Young Men—A Review of the Prevalence and Risk Factors
Nguyen, H. M. T., Gabrielson, A. T., & Hellstrom, W. J. G. (2017) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2017.05.004 · Cited by 345
Tadalafil in the treatment of erectile dysfunction
Coward, R., & Carson, C. (2008) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s3336 · Cited by 138
Self-citation
Metadata
- Authors
- Carson, C. C., & Lue, T. F.
- Venue
- BJU International
- Publisher
- Wiley
- Published
- 2005-07-24
- Volume
- 96
- Issue
- 3
- Pages
- 257-280
- ISSN
- 1464-4096 (ISSN-L)
- 1464-410X
- OpenAlex
- W2022738955
- Cited by
- 202
- References
- 8
- FWCI
- 11.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phosphodiesterase type 5 inhibitors for erectile dysfunction. https://app.cochat.ai/papers/10.1111/j.1464-410x.2005.05614.x
- The paper
- Carson, C. C., & Lue, T. F. (2005). Phosphodiesterase type 5 inhibitors for erectile dysfunction. BJU International. https://doi.org/10.1111/j.1464-410x.2005.05614.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.